VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, announced changes to its Board of Directors, effective immediately. Janusz Grabski has resigned from the Board, and the Board has formally appointed Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, as a director. This appointment follows the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The changes are intended to ensure that the Board continues to meet Helix's evolving governance and capital markets requirements, and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The Board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
These board changes come at a critical time as Helix advances its clinical programs. The appointment of Dr. Mehrling, who has been leading the company's strategic direction, is expected to strengthen the alignment between management and the board. According to the company, the board's new composition will better support its clinical development and corporate objectives, which include progressing L-DOS47 through clinical trials and advancing its pre-IND candidates toward the clinic.
The resignation of Mr. Grabski and the appointment of Dr. Mehrling reflect a broader trend in the biotech industry where companies are streamlining governance to focus on execution and value creation. For Helix, this move may signal a renewed emphasis on advancing its pipeline and potentially seeking partnerships or financing to support its programs. The company's shares are listed on the Toronto Stock Exchange, OTC Pink Market, and Frankfurt Stock Exchange, indicating a diverse investor base that will be watching these developments closely.
The impact of these changes is likely to be felt across the company's operations, as board composition often influences strategic decisions, capital allocation, and investor confidence. With Dr. Mehrling now on the board, there is a clearer line of sight into the company's clinical and corporate strategy, which may help in articulating the company's vision to stakeholders. The company's website provides further details on its pipeline and recent strategic acquisition, which can be accessed at https://www.helixbiopharma.com/.
Helix BioPharma's ongoing efforts to develop treatments for difficult-to-treat cancers underscore the importance of strong governance in navigating the complex landscape of oncology drug development. As the company moves forward, the board's revised composition will be instrumental in guiding its path toward potential milestones, including clinical trial results and regulatory interactions. The company's recent acquisition from the Laevoroc group, detailed in a press release, highlights its commitment to expanding its pipeline with innovative candidates.
